Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | DHODH | Q02127 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25380521 | 0.88 | MEN1 (0.50) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL30120604 | 0.83 | RXFP1 (0.57) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL13919569 | 0.83 | RXFP1 (0.57) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL11669167 | 0.81 | ALDH1A1 (0.71) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL31266680 | 0.81 | DHODH (0.62) | RXFP1MEN1KMT2ANPC1PPARG | |
| SCHEMBL8703497 | 0.79 | EPRS1 (0.58) | MEN1KMT2AALDH1A1KDM4EDHODH | |
| SCHEMBL2655065 | 0.79 | ALDH1A1 (0.63) | RXFP1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL15322624 | 0.79 | ALDH1A1 (0.64) | RXFP1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL7399715 | 0.79 | ALDH1A1 (0.65) | KMT2AALDH1A1KDM4EDHODHPOLB | |
| SCHEMBL16832575 | 0.79 | RXFP1 (0.56) | RXFP1MEN1KMT2ANPC1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098450-A1 | PRMT5 INHIBITOR AND PREPARATION METHOD THEREFOR | 北京泰德制药股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| US-20220315568-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021050913-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-2684167-B1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-9345700-B2 | Compositions and methods useful for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345700-B2 | Compositions and methods useful for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345700-B2 | Compositions and methods useful for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150352097-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| EP-2479578-A1 | Mass defect labeling for the determination of oligomer sequences | Target Discovery, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-22 | — | — | US | disclosed |
| US-7316931-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7316931-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060073485-A1 | Mass defect labeling for the determination of oligomer sequences | TAGET DISCOVERY, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| US-6962818-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1358458-A2 | MASS DEFECT LABELING FOR THE DETERMINATION OF OLIGOMER SEQUENCES | Target Discovery, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020172961-A1 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002066952-A2 | MASS DEFECT LABELING FOR THE DETERMINATION OF OLIGOMER SEQUENCES | TARGET DISCOVERY, INC (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099683-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | RXFP1 4695/4885MEN1 2792/4885KMT2A 1608/4885 |
| US-20150352097-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | BCL3, MCL1, BCL6 | RXFP1 4860/4885MEN1 720/4885KMT2A 1038/4885 |
| US-20220315568-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | RXFP1 4432/4885MEN1 4363/4885KMT2A 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.